國家衛生研究院 NHRI:Item 3990099045/10639

NHRI > National Institute of Infectious Diseases and Vaccinology > Shu-Chen Kuo > Periodical Articles > Item 3990099045/10639

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10639

Title:	Multicenter study of clinical features of breakthrough acinetobacter bacteremia during carbapenem therapy
Authors:	Lee, YT;Wang, YC;Kuo, SC;Chen, CT;Liu, CP;Liu, YM;Chen, TL;Yang, YS
Contributors:	Division of Infectious Diseases
Abstract:	Breakthrough Acinetobacter bacteremia during carbapenem therapy is not uncommon and creates therapeutic dilemmas for clinicians. This study was conducted to evaluate the clinical and microbiological characteristics of breakthrough Acinetobacter bacteremia during carbapenem therapy and to assess the efficacy of various antimicrobial therapies. We analyzed 100 adults who developed breakthrough Acinetobacter bacteremia during carbapenem therapy at 4 medical centers over a 6-year period. Their 30-day mortality rate was 57.0% and the carbapenem resistance rate of their isolates was 87.0%. Among patients with carbapenem-resistant Acinetobacter bacteremia, breakthrough bacteremia during carbapenem therapy was associated with a significant higher 14-day mortality (51.7% versus 37.4%, P = 0.025 by bivariate analysis) and a higher 30-day mortality (P = 0.037 by log-rank test of survival analysis) than in the non-breakthrough group. For treatment of breakthrough Acinetobacter bacteremia during carbapenem therapy, tigecycline-based therapy was associated with a significantly higher 30-day mortality (80.0%) than continued carbapenem therapy (52.5%) and colistin-based therapy (57.9%) by survival analysis (P = 0.047 and 0.045 by log-rank test, respectively). Cox regression controlling for confounders, including severity of illness indices, demonstrated that patients treated with tigecycline-based therapy for breakthrough Acinetobacter bacteremia was an independent predictor of 30-day mortality (hazard ratio, 3.659; 95% confidence interval, 1.794-7.465; P < 0.001). Patients with breakthrough Acinetobacter bacteremia during carbapenem therapy posed a poor outcome. Tigecycline should be used cautiously for treatment of breakthrough Acinetobacter bacteremia that develops during carbapenem therapy.
Date:	2017-09
Relation:	Antimicrobial Agents and Chemotherapy. 2017 Aug;61(9):Article number e00931-17.
Link to:	http://dx.doi.org/10.1128/aac.00931-17
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000408309000063
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85028311922
Appears in Collections:	[Shu-Chen Kuo] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB28674056.pdf		344Kb	Adobe PDF	325	View/Open

Loading...